Home - STREXIT2

Retroperitoneal sarcomas are rare diseases for which the current standard treatment is surgery.

STREXIT2 project

STREXIT2 is proposed to complement the ongoing phase III EORTC clinical trial STRASS2 investigating the added value of neoadjuvant chemotherapy before surgery for high-risk retroperitoneal sarcoma and to add an observational study STREXIT2 that will capture real world data from patients not participating to STRASS2.

About retroperitoneal sarcomas

Retroperitoneal sarcomas are rare diseases refractory to treatment with poor prognosis. Surgery the current standard approach to primary disease. We are proposing an innovative pragmatic approach supplementing a standard phase III clinical trial with an observational cohort.

Learn more

Economic Evaluation

We will perform health economics analysis assessing the economic value of different treatment scenarios based on STRASS2 and STREXIT2. If successful, the outcomes of the project will define a new evidence-based standard of care for high-risk retroperitoneal sarcomas.

About Strexit 2

Who we are

We are a multidisciplinary and multistakeholder consortium involving clinical oncologists, surgeons, health economists and patient representatives. The study design was successfully discussed with patients. This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.

Understanding of cancer

Prevention and early detection

Diagnosis and treatment

Quality of life for patients and their families

In the media

Coming soon.

Our Blog

Lates News & Articles

Blog

Bringing Research Closer to Patients: How Pragmatic Trial Designs Can Transform Rare Cancer Research

Traditional clinical trials are essential for determining whether new treatments are safe and effective. However, the highly controlled conditions...

Blog

Exploring Clinical Innovation: A New Blog Series

We are happy to announce a new blog series created in collaboration between the Sarcoma Patient Advocacy Global...

Blog

The objectives of the STREXIT 2 Project in the words of Principal Investigator and Co-Leader Dr Winan van Houdt

STREXIT 2 is part of a series of clinical trials funded by the Horizon Europe programme as part...

PRIVACY POLICY & LEGAL NOTICE

© The STREXIT2 Consortium 2023-2028. This project has received funding from the European Union’s HORIZON-MISS-CANCER-2022-01 under grant agreement Nº (101103843). Views and opinions expressed are however those of the authors only and do not necessarily
reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.